Avantor Inc

Sector Focus

Biomedical, life science sectors in focus as Biopolis turns 20; CapitaLand revives Science Park Drive

“We spend a lot of effort encouraging many companies to use Singapore as a base, and also try to leverage our investment and R&D.”
Avantor: Underperforming pharma play but financial ratios remain healthy - THE EDGE SINGAPORE

Global stocks

Avantor: Underperforming pharma play but financial ratios remain healthy

Avantor is the global provider of mission-critical products and services to customers including the biopharma sector.
Navigating a chaotic year - THE EDGE SINGAPORE

Global stocks

Navigating a chaotic year

The Edge Singapore’s 2022 virtual global portfolio returned -9.8% for the period of Feb 7, 2022, to Jan 13, 2023.
Avantor: Integrated biopharma vanguard - THE EDGE SINGAPORE

Global stocks

Avantor: Integrated biopharma vanguard

The company’s one-year total return was –41.4% although its financials were mostly intact.
Standing pat, staying put - THE EDGE SINGAPORE

Global stocks

Standing pat, staying put

Our 2022 portfolio lost 11.8% in the four-month period from Feb 7 to June 17, with eight losers in the portfolio.

Global stocks

Avantor: Key play for investors seeking value and biotechnology exposure

New York-listed Avantor Inc was among the underperformers in our portfolio for the four-month period, with a 18.0% loss.
Avantor: Driven by Covid vaccine, demand from biopharma - THE EDGE SINGAPORE

Global stocks

Avantor: Driven by Covid vaccine, demand from biopharma

Strong margins and attractive yields give Avantor a competitive edge.
Our top 10 global stocks for 2022 - THE EDGE SINGAPORE

Global stocks

Our top 10 global stocks for 2022

Here’s our 10 global stock picks for this year.
×